SHPH Shuttle Pharmaceuticals Holdings, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1757499 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY15.5%
TTM EPS YoY158.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-90.1%
ROA-72.5%
ROIC (approx.)-99.2%
Asset turnover—
Leverage & solvency
Liabilities / assets15.9%
Debt / equity0.00x
Current ratio0.11x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.64x
Accruals ratio-26.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 | 2024Q32024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $55,661 | $267,240 | $511,878 | $943,478 | $1.03M | $1.57M | $986,409 | $1.40M |
| SG&A expense | $1.98M | $1.16M | $1.84M | $886,055 | $2.35M | $596,886 | $429,067 | $328,995 |
| Operating income | -$3.95M | -$2.22M | -$2.79M | -$2.27M | -$3.91M | -$2.95M | -$1.78M | -$3.05M |
| Net income | -$3.15M | -$2.15M | -$2.61M | -$2.35M | -$3.71M | -$3.05M | -$1.60M | -$3.78M |
| EBITDA | -$3.32M | -$1.58M | -$2.50M | -$2.27M | -$3.91M | -$2.95M | -$1.78M | -$3.05M |
| EPS (basic) | -3.10 | -0.43 | — | -1.05 | -32.91 | -7.60 | — | -39.83 |
| EPS (diluted) | -3.10 | -0.43 | — | -1.05 | -32.91 | -7.60 | — | -39.83 |
| Weighted avg. shares (diluted) | 1.02M | 5.03M | — | 2.23M | 112,611 | 401,957 | — | 95,004 |
| Balance sheet | ||||||||
| Cash & equivalents | $90,238 | $1.09M | $334,005 | $2.09M | $4.82M | $4.51M | $1.92M | $156,656 |
| Current assets | $396,353 | $2.46M | $502,911 | $3.27M | $5.19M | $4.96M | $2.21M | $361,351 |
| PP&E, net | $15,191 | $16,311 | $17,319 | $18,327 | $19,335 | $18,356 | $19,364 | $21,160 |
| Intangibles | $8.65M | $9.24M | $9.84M | — | — | — | — | — |
| Total assets | $22.81M | $11.81M | $10.48M | $3.54M | $5.50M | $5.31M | $2.51M | $673,568 |
| Current liabilities | $3.48M | $8.31M | $7.97M | $1.96M | $1.69M | $1.78M | $1.53M | $1.66M |
| Total liabilities | $3.63M | $8.46M | $8.22M | $2.15M | $1.90M | $2.02M | $1.80M | $1.99M |
| Shareholders' equity | $19.18M | $3.35M | $2.25M | $1.39M | $3.61M | $3.29M | $709,152 | -$1.32M |
| Shares outstanding | 1.00M | 5.55M | 202,362 | 1.24M | 1.07M | 6.38M | 163,093 | 2.95M |
| Cash flow statement | ||||||||
| Operating cash flow | -$567,640 | -$2.42M | -$973,012 | -$2.63M | -$3.36M | -$2.53M | -$2.69M | -$2.00M |
| Investing cash flow | -$5.43M | -$36,000 | — | — | — | — | $0 | $1.66M |
| Financing cash flow | $5.00M | $3.21M | $2.27M | -$96,375 | $3.66M | $5.12M | $4.45M | -$196,790 |
| Depreciation & amortization | $633,451 | $633,340 | $289,070 | $1,008 | -$979 | $1,008 | $1,796 | $793 |
| Stock-based compensation | -$7,511 | $35,018 | $214,750 | $134,318 | $46,853 | $537,046 | $31,858 | $45,275 |
Free plan shows the latest 8 periods; Pro shows all 22 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.